Drug Information
Drug (ID: DG00527) and It's Reported Resistant Information
| Name |
Tixagevimab/Cilgavimab
|
||||
|---|---|---|---|---|---|
| Drug Resistance Disease(s) |
Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug
(1 diseases)
COVID-19 [ICD-11: 1D92]
[1]
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
| DrugBank ID | |||||
Type(s) of Resistant Mechanism of This Drug
ADTT: Aberration of the Drug's Therapeutic Target
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-01: Infectious/parasitic diseases
COVID-19 [ICD-11: 1D92]
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
Aberration of the Drug's Therapeutic Target (ADTT)
|
||||
| Key Molecule: Moesin (MSN) | [1] | |||
| Resistant Disease | Corona Virus Disease 2019 [ICD-11: 1D92.0] | |||
| Molecule Alteration | Mutations | L100I + K103N + P225H |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | Vero E6 cells | Kideny | Homo sapiens (Human) | N.A. |
| BHKG43 cells | Kideny | Homo sapiens (Human) | N.A. | |
| HEK 293T cells | Kidney | Homo sapiens (Human) | CVCL_0063 | |
| Experiment for Molecule Alteration |
qRT-PCR; Deep sequencing assay | |||
| Experiment for Drug Resistance |
Immunofluorescence assay | |||
| Mechanism Description | Monoclonal antibodies targeting the Spike protein of SARS-CoV-2 are effective against COVID-19 and might mitigate future pandemics. However, their efficacy is challenged by the emergence of antibody-resistant virus variants. | |||
| Key Molecule: Moesin (MSN) | [1] | |||
| Resistant Disease | Corona Virus Disease 2019 [ICD-11: 1D92.0] | |||
| Molecule Alteration | Mutations | L2003M |
||
| Experimental Note | Revealed Based on the Cell Line Data | |||
| In Vitro Model | Hela cells | Cervix uteri | Homo sapiens (Human) | CVCL_0030 |
| Experiment for Molecule Alteration |
qRT-PCR; Deep sequencing assay | |||
| Experiment for Drug Resistance |
Immunofluorescence assay | |||
| Mechanism Description | Monoclonal antibodies targeting the Spike protein of SARS-CoV-2 are effective against COVID-19 and might mitigate future pandemics. However, their efficacy is challenged by the emergence of antibody-resistant virus variants. | |||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.